Vorinostat
Nasopharyngeal Squamous Cell Carcinoma
Explore 6 assets in Nasopharyngeal Squamous Cell Carcinoma →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
AIDS Malignancy Consortium
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01249443CT.gov Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | — | Terminated | — | — | — |
NCT00336063CT.gov Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Nasopharyngeal Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vorinostat (this asset) | AIDS Malignancy Consortium | P1 | CC · 43 |
| Cetuximab | National Cancer Institute (NCI) | P1/2 | B |
| Irinotecan | AIDS Malignancy Consortium | P1/2 | B |
| Carboplatin | Rapa Therapeutics LLC | P1/2 | B |
| Pembrolizumab | Rapa Therapeutics LLC | P1/2 | CCC |
| Autologous Rapamycin-Resistant Th1/Tc1 Cells Rapa-201 | Rapa Therapeutics LLC | P1/2 | CCC |
| Everolimus | Fox Chase Cancer Center | P1 | CC |
| Recombinant Interleukin-12 | National Cancer Institute (NCI) | P1 | CC |
| Abi-007 | National Cancer Institute (NCI) | P1 | CC |
+7 more in the Nasopharyngeal Squamous Cell Carcinoma cohort
Other indications for Vorinostat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P2 | BB · 68 |
| Hodgkins Lymphoma | — | P2 | BB · 68 |
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vorinostat in Nasopharyngeal Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vorinostat-nasopharyngeal-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →